Structure and properties of pharmacologically active polymers
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Although the concept of using pharmacologically active macromolecular compounds as drugs is still regarded with much skepticism for both theoretical and practical reasons, interest in this field has grown in recent years because of the opportunity to take advantage of the specific properties of polymeric materials. For low molecular weight drugs, changes in structure often lead to a loss of specific activity. On the other hand, the properties of macromolecular drugs depend on the structure of the polymer used and this can be varied over a wide range by the incorporation of comonomer units, by the application of polymer‐analogous reactions, or by related structural changes. A new model is presented for pharmacologically active polymers which incorporates the possibility for continuous variation in (a) solubility and toxicity, (b) fixation and removal of active material, and (c) body distribution. Using the new model as a guide, examples of the synthesis and study of the biological activity of various macromolecular drugs are presented in order to emphasize the importance of this cooperative effort between polymer research and therapeutic problems.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The drug-polymer conjugates were introduced in the early work by Helmut Ringsdorf in 1970s to improve drug solubility, toxicity, and body biodistribution, which was followed by extensive studies on the development of drug-polymer conjugates [143, 144].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [144]
Citations
Cites
de Duve, C., & Wattiaux, R. (1966) · Annual Review of Physiology · doi:10.1146/annurev.ph.28.030166.002251 · Cited by 3,033
De Duve, C., De Barsy, T., Poole, B., Trouet, A., Tulkens, P., & Van Hoof, F. (1974) · Biochemical Pharmacology · doi:10.1016/0006-2952(74)90174-9 · Cited by 1,901
Chang, T. M. S. (1964) · Science · doi:10.1126/science.146.3643.524 · Cited by 1,011
Lysosomes in Biology and Pathology
Lagunoff, D. (1974) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1974.03230160059035 · Cited by 887
AN EXAMINATION OF THE CYTOTOXIC EFFECTS OF SILICA ON MACROPHAGES
Allison, A. C., Harington, J. S., & Birbeck, M. (1966) · The Journal of Experimental Medicine · doi:10.1084/jem.124.2.141 · Cited by 871
FACTOR-VIII COMPLEX AND ENDOTHELIAL DAMAGE
Boneu, B., Abbal, M., Plante, J., & Bierme, R. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92650-1 · Cited by 716
de Duve, C. (2008) · Novartis Foundation Symposia · doi:10.1002/9780470715314.ch1 · Cited by 473
DRUG-CARRIER POTENTIAL OF LIPOSOMES IN CANCER CHEMOTHERAPY
Gregoriadis, G., Swain, C. P., Wills, E. J., & Tavill, A. S. (1974) · The Lancet · doi:10.1016/s0140-6736(74)90682-5 · Cited by 401
Poly[N-(2-hydroxypropyl)methacrylamide]—I. Radical polymerization and copolymerization
Kopeček, J., & Baẑilová, H. (1973) · European Polymer Journal · doi:10.1016/0014-3057(73)90063-3 · Cited by 300
Ryser, H. J.-P. (1968) · Science · doi:10.1126/science.159.3813.390 · Cited by 288
Research works printed but not linked: 20
- Lee H., 1971, Handbook for Surgery and Artificial Organs
- Kabaiwanow W., 1972, Plaste Kaut., 19, 886
- Wessel W., 1971, Arzeim. Forsch., 21, 1468
- Ryser H. J. P., 1970, Proc. Fourth Int. Cong. Pharm., 3, 96
- 1965, Silikose Forsch., 6, 213
- Ferruti P., 1966, Med. Lav., 57, 481
- V.Hofmann dissertation University of Mainz 1975.
- Burger A., 1970, Medicinal Chemistry, 1185
- Donaruma L. G., 1974, Prog. Polym. Sci., 4, 18
- G.Franzmann dissertation University of Mainz 1975.
- H.Morawetzet al. in press.
- Ringsdorf H., 1967, Strahlentherapie, 132, 627
- Busch H., 1961, Cancer Res., 21, 271
- H.Ritter dissertation University of Mainz 1975.
- M.Przybylski dissertation University of Mainz 1975.
- Jacob S. W., 1971, Dimethylsulfoxide
- V.Hofmann H.Ringsdorf andG.Muacevic Makromol. Chem. in press.
- Jacques P. J., 1966, Rev. Quest. Sci., 27, 99
- Jacques P. J., 1969, Lysosomes in Biology and Pathology, 395
- Szekerke M., 1972, Neoplasma, 19, 211
Cited by
Items 201–300 of 1,000
Modifying the Body Distribution of HPMA-Based Copolymers by Molecular Weight and Aggregate Formation
Allmeroth, M., Moderegger, D., Biesalski, B., Koynov, K., Rösch, F., Thews, O., & Zentel, R. (2011) · Biomacromolecules · doi:10.1021/bm2005774 · Cited by 95
Innovative Design of Targeted Nanoparticles: Polymer–Drug Conjugates for Enhanced Cancer Therapy
Junyaprasert, V. B., & Thummarati, P. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092216 · Cited by 92
“In this model, it was env sioned that the drug-attache polymeric carrier could not only be modulated, but al o that active targeting could be achieved by int oducing a homing moiety into the same polymeric carrier [19].”
BackgroundMethodResultInfluentialPolymer conjugates as therapeutics: future trends, challenges and opportunities
Vicent, M. J., Dieudonne, L., Carbajo, R. J., & Pineda‐Lucena, A. (2008) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.5.5.593 · Cited by 98
“The rationale for the use of polymers as carriers of conjugated therapeutics was well described by Helmut Ringsdorf [17] , tuning the pioneering work of Jatzkewitz, who used nondegradable or enzymatically degradable (glycyl- L -leucine) side chains to conjugate the psychedelic alkaloid drug mescaline to N -vinylpyrrol…”
BackgroundBiological Activity of a Gallic Acid−Gelatin Conjugate
Cirillo, G., Kraemer, K., Fuessel, S., Puoci, F., Curcio, M., Spizzirri, U. G., Altimari, I., & Iemma, F. (2010) · Biomacromolecules · doi:10.1021/bm100760x · Cited by 86
An, Z., Qiu, Q., & Liu, G. (2011) · Chemical Communications · doi:10.1039/c1cc13955j · Cited by 85
Kopec̆ek, J. (1977) · Die Makromolekulare Chemie · doi:10.1002/macp.1977.021780804 · Cited by 84
Liposome–ligand conjugates: a review on the current state of art
Eroğlu, İ., & İbrahim, M. (2019) · Journal of drug targeting · doi:10.1080/1061186x.2019.1648479 · Cited by 86
“The use of PEG spacers is advantageous especially when a high water solubility of the conjugate is required; however, PEG spacers cannot dissolve within the lipid bilayer structure [62,72].”
BackgroundChang, Y., Chen, J., Yang, J., Lin, T., Zeng, L., Xu, J., Hou, J., & Zhang, X. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b13492 · Cited by 83
Melnyk, T., Đorđević, S., Conejos‐Sánchez, I., & Vicent, M. J. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.10.007 · Cited by 87
Design and Synthesis of Polymeric Hydrogen Sulfide Donors
Hasegawa, U., & van der Vlies, A. J. (2014) · Bioconjugate Chemistry · doi:10.1021/bc500150s · Cited by 83
Biofunctional nanosystems based on dendritic polymers
Quadir, M., & Haag, R. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.12.040 · Cited by 82
Pawełczyk, A., Sowa‐Kasprzak, K., Olender, D., & Zaprutko, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19041104 · Cited by 87
Incorporation of Ru(II) Polypyridyl Complexes into Nanomaterials for Cancer Therapy and Diagnosis
Soliman, N., Gasser, G., & Thomas, C. M. (2020) · Advanced Materials · doi:10.1002/adma.202003294 · Cited by 82
Loyer, P., & Cammas‐Marion, S. (2014) · Journal of drug targeting · doi:10.3109/1061186x.2014.936871 · Cited by 82
“a degradable bound and (iii) targeting agents and body distribution modulator groups [11].”
BackgroundRelevance of folic acid/polymer ratio in targeted PEG–epirubicin conjugates
Canal, F., Vicent, M. J., Pasut, G., & Schiavon, O. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.05.027 · Cited by 82
Covalent nano delivery systems for selective imaging and treatment of brain tumors
Ljubimova, J. Y., Sun, T., Mashouf, L. A., Ljubimov, A. V., Israel, L. L., Ljubimov, V. A., Falahatian, V., & Holler, E. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.06.002 · Cited by 86
Voltage-responsive micelles based on the assembly of two biocompatible homopolymers
Liao, P., Feng, A., Zhang, H., Wang, H., Jian, C., Liu, B., Gao, W., & Yuan, J. (2013) · Polymer Chemistry · doi:10.1039/c3py01204b · Cited by 81
Scomparin, A., Salmaso, S., Eldar‐Boock, A., Ben‐Shushan, D., Ferber, S., Tiram, G., Shmeeda, H., Landa‐Rouben, N., Leor, J., Caliceti, P., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.009 · Cited by 81
“On the basis of Ringsdorf's polymeric carrier concept [31,32], we recently developed a conjugate ofDoxusingpullulan as thepolymeric backbone [33].”
MethodHaririan, I. (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s8595 · Cited by 81
Raveendran, R., Bhuvaneshwar, G. S., & Sharma, C. P. (2015) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2015.11.017 · Cited by 84
A biomimic pH-sensitive polymeric prodrug based on polycarbonate for intracellular drug delivery
Wang, H., Wang, Y., Chen, Y., Jin, Q., & Ji, J. (2013) · Polymer Chemistry · doi:10.1039/c3py00861d · Cited by 83
Nanocarriers for the targeted treatment of ovarian cancers
Tomasina, J., Lheureux, S., Gauduchon, P., Rault, S., & Malzert‐Fréon, A. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.10.055 · Cited by 88
Polymeric Systems of Antimicrobial Peptides—Strategies and Potential Applications
Sobczak, M., Debek, C., Olędzka, E., & Kozlowski, R. M. (2013) · Molecules · doi:10.3390/molecules181114122 · Cited by 89
“In 1975, Ringsdorf proposed a model for the rational design of polymeric prodrugs [9,77].”
BackgroundDesign of “Smart” polymers that can direct intracellular drug delivery
Hoffman, A. S., Stayton, P. S., Press, O. W., Murthy, N., Lackey, C. A., Cheung, C., Black, F. E., Campbell, J. S., Fausto, N., Kyriakides, T. R., et al. (2002) · Polymers for Advanced Technologies · doi:10.1002/pat.232 · Cited by 80
Noyhouzer, T., L’Homme, C., Beaulieu, I., Mazurkiewicz, S., Kuss, S., Kraatz, H., Canesi, S., & Mauzeroll, J. (2016) · Langmuir · doi:10.1021/acs.langmuir.6b00511 · Cited by 79
Thapa, R. K., Diep, D. B., & Tønnesen, H. H. (2021) · Journal of Pharmaceutical Investigation · doi:10.1007/s40005-021-00525-z · Cited by 82
“Prodrugs (inactive precursors) of the AMPs can be prepared by their covalent attachment to the synthetic polymers via a physiologically labile bond (e.g. amide, ester, carbonate, anhydride) (Ringsdorf 1975).”
BackgroundYang, J., & Kopec̆ek, J. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.04.013 · Cited by 84
“Finally, Ringsdorf analyzed the research results of the field and presented a clear concept of the use of polymers as targetable drug carriers [35].”
BackgroundChemical Approaches to Synthetic Drug Delivery Systems for Systemic Applications
Braatz, D., Cherri, M., Tully, M., Dimde, M., Ma, G., Mohammadifar, E., Reisbeck, F., Ahmadi, V., Schirner, M., & Haag, R. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202203942 · Cited by 80
Design and development of polymer conjugates as anti-angiogenic agents
Segal, E., & Satchi‐Fainaro, R. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.06.005 · Cited by 81
“The concept of a drug delivery system based on synthetic polymers was first proposed by Helmut Ringsdorf in 1975 [4].”
BackgroundChemical modifications of polydiene elastomers: A survey and some recent results
Brosse, J., Campistron, I., Derouet, D., Hamdaoui, A., Mulder‐Houdayer, S., Reyx, D., & Ritoit-Gillier, S. (2000) · Journal of Applied Polymer Science · doi:10.1002/1097-4628(20001121)78:8<1573::aid-app150>3.0.co;2-p · Cited by 77
Hybrid Polymer Therapeutics Incorporating Bioresponsive, Coiled Coil Peptide Linkers
Apostolovic, B., Deacon, S. P. E., Duncan, R., & Klok, H. (2010) · Biomacromolecules · doi:10.1021/bm901313c · Cited by 77
Multivalent Polymers for Drug Delivery and Imaging: The Challenges of Conjugation
van Dongen, M. A., Dougherty, C. A., & Holl, M. M. B. (2014) · Biomacromolecules · doi:10.1021/bm500921q · Cited by 87
Synthetic Polymers as Drug-Delivery Vehicles in Medicine
Neuse, E. W. (2008) · Metal-Based Drugs · doi:10.1155/2008/469531 · Cited by 76
“The notion of pairing up a bioactive agent with a transporter vehicle, born in the early 1970s, was forcefully advanced by Ringsdorf [4], who defined and refined this paradigm in palpable terms and set in motion broad-based development activities in numerous laboratories, on the strength of which the notion has by now…”
BackgroundPEG based anti-cancer drug conjugated prodrug micelles for the delivery of anti-cancer agents
Senevirathne, S. A., Washington, K. E., Biewer, M. C., & Stefan, M. C. (2016) · Journal of Materials Chemistry B · doi:10.1039/c5tb02053k · Cited by 80
Ooya, T., & Yui, N. (1997) · Journal of Biomaterials Science Polymer Edition · doi:10.1163/156856297x00371 · Cited by 76
HPMA Copolymer–Drug Conjugates with Controlled Tumor‐Specific Drug Release
Chytil, P., Randárová, E., Etrych, T., & Ulbrich, K. (2017) · Macromolecular Bioscience · doi:10.1002/mabi.201700209 · Cited by 78
van (2010) · International Journal of Nanomedicine · doi:10.2147/ijn.s13482 · Cited by 79
Nanotechnology in Drug Delivery
Emeje, M. O., Ezenyi, I. C., Akpabio, E. I., & Ifianyi, S. (2012) · InTech eBooks · doi:10.5772/51384 · Cited by 74
“The idea started in 1975 when Ringsdorf proposed the use of polymer–drug conjugates to deliver hydrophobic small molecules (34).”
BackgroundGündüz, U., Keskin, T., Tansık, G., Mutlu, P., Yalçın, S., Ünsoy, G., Yakar, A., Khodadust, R., & Gündüz, G. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.08.013 · Cited by 74
Polypeptides and polyaminoacids in drug delivery
González-Aramúndiz, J. V., Lozano, M. V., Sousa‐Herves, A., Fernández-Megía, E., & Csaba, N. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.647906 · Cited by 81
“In the mid-1970s, Ringsdorf [24] proposed that polymer--drug conjugates could enhance the delivery of anticancer drugs to tumors.”
BackgroundAstruc, D. (2015) · Molecules · doi:10.3390/molecules21010004 · Cited by 74
“Seminal works on nanoparticles for nanomedicine were increasingly developed in the last 30 years of the 20th century and included liposomes [10,11], DNA-drug complexes [12], polymer-drug conjugates [13], antibody-drug conjugates [14], polymer nanocapsules [15–17], polymer-protein conjugates [18], albumin-drug conjugat…”
BackgroundPiotrowska, U., Sobczak, M., & Oledzka, E. (2017) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13031 · Cited by 70
Grayson, S. M., & Godbey, W. T. (2008) · Journal of drug targeting · doi:10.1080/10611860801969616 · Cited by 81
“As an extension of this concept, Ringsdorf (1975) proposed the bold goal of designing the ideal therapeutic by tailoring the critical properties of the macromolecular carriers: including molecular weight, drug loading, targeting moieties, and triggered drug release.”
BackgroundCyclic peptide–polymer conjugates: Grafting‐to vs grafting‐from
Larnaudie, S. C., Brendel, J. C., Jolliffe, K. A., & Perrier, S. (2015) · Journal of Polymer Science Part A Polymer Chemistry · doi:10.1002/pola.27937 · Cited by 72
Fleming, C., Maldjian, A., Costa, D. D., Rullay, A. K., Haddleton, D. M., John, J. C. S., Penny, P. C., Noble, R. C., Cameron, N. R., & Davis, B. G. (2005) · Nature Chemical Biology · doi:10.1038/nchembio730 · Cited by 72
“Such multicomponent polymers are an embodiment of a prior prescient concep”
BackgroundSynthesis of Organic Nanoparticles
Romero, G., & Moya, S. E. (2012) · Frontiers of nanoscience · doi:10.1016/b978-0-12-415769-9.00004-2 · Cited by 72
Mansur, A. A. P., Carvalho, S. M., Lobato, Z. I. P., Leite, M. F., Silva‐Cunha, A., & Mansur, H. S. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00208 · Cited by 74
Optimization of macromolecular prodrugs of the antitumor antibiotic adriamycin
Hoes, C. J. T., Potman, W., van Heeswijk, W. A. R., Mud, J., Grooth, B. G. D., Greve, J., & Feijén, J. (1985) · Journal of Controlled Release · doi:10.1016/0168-3659(85)90046-x · Cited by 77
RAFT-synthesized copolymers and conjugates designed for therapeutic delivery of siRNA
Smith, D., Holley, A. C., & McCormick, C. L. (2011) · Polymer Chemistry · doi:10.1039/c1py00038a · Cited by 81
Kakinoki, A., Kaneo, Y., Ikeda, Y., Tanaka, T., & Fujita, K. (2008) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.31.103 · Cited by 69
Promising nanomaterials in the fight against malaria
Borgheti-Cardoso, L. N., Anselmo, M. S., Lantero, E., Lancelot, A., Serrano, J. L., Hernández‐Ainsa, S., Fernàndez‐Busquets, X., & Sierra, T. (2020) · Journal of Materials Chemistry B · doi:10.1039/d0tb01398f · Cited by 77
Dual pH-responsive-charge-reversal micelle platform for enhanced anticancer therapy
Liao, J., Peng, H., Liu, C., Li, D., Yin, Y., Lu, B., Zheng, H., & Wang, Q. (2021) · Materials Science and Engineering: C · doi:10.1016/j.msec.2020.111527 · Cited by 68
Polymer‐Bound Thiol Groups on Poly(2‐oxazoline)s
Cesana, S., Kurek, A., Baur, M. A., Auernheimer, J., & Nuyken, O. (2007) · Macromolecular Rapid Communications · doi:10.1002/marc.200600737 · Cited by 70
Pierre, T. S., & Chiellini, E. (1986) · Journal of Bioactive and Compatible Polymers · doi:10.1177/088391158600100405 · Cited by 78
Drug Delivery Systems Based on Hydroxyethyl Starch
Paleos, C. M., Sideratou, Z., & Tsiourvas, D. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00186 · Cited by 70
Supramolekulare Wirkstoff‐Transportsysteme auf der Basis polymerer Kern‐Schale‐Architekturen
Haag, R. (2003) · Angewandte Chemie · doi:10.1002/ange.200301694 · Cited by 72
Trojan horses and guided missiles: targeted therapies in the war on arthritis
Ferrari, M., Onuoha, S. C., & Pitzalis, C. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.17 · Cited by 69
Exploiting EPR in Polymer Drug Conjugate Delivery for Tumor Targeting
Modi, S., Jain, J. P., Domb, A. J., & Kumar, N. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779026272 · Cited by 69
“Since the pioneering studies of Ringsdorf [87], PDCs emerges as significant avenue in pharmaceutical sciences owing to-”
BackgroundIn vitro cytotoxicity of poly(amidoamine)s: relevance to DNA delivery
Hill, I. R. (1999) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/s0304-4165(99)00021-5 · Cited by 69
Singh, M., Bhatnagar, P., Mishra, S., Kumar, P., Shukla, Y., & Gupta, K. C. (2015) · International Journal of Nanomedicine · doi:10.2147/ijn.s79489 · Cited by 66
“Polymer-drug conjugates, macromolecular prodrugs, which were first developed in the mid1970s, have laid the foundation for new types of anticancer entities.(17) Among them, poly(lactide-co-glycolide) (PLGA, 50:50 approved by the US Food and Drug Administration) has been used in the preparation of a wide variety of dru…”
BackgroundRetractedElastin-like polypeptides and their applications in anticancer drug delivery systems: a review
Saxena, R., & Nanjan, M. J. (2013) · Drug Delivery · doi:10.3109/10717544.2013.853210 · Cited by 72
“In particular, Lysosomotropic polymerdrug conjugates, block copolymer micelles and PEG-protein conjugates came into consideration due to the revolutionary work of De Duve et al. (1974), Ringsdorf (1975), Abuchowski et al. (1977) and others.”
BackgroundPolypeptide‐Based Conjugates as Therapeutics: Opportunities and Challenges
Zagorodko, O., Arroyo‐Crespo, J. J., Nebot, V. J., & Vicent, M. J. (2016) · Macromolecular Bioscience · doi:10.1002/mabi.201600316 · Cited by 71
Design of Drug Delivery Systems Containing Artemisinin and Its Derivatives
Aderibigbe, B. A. (2017) · Molecules · doi:10.3390/molecules22020323 · Cited by 75
Burgio, S., Noori, L., Marino Gammazza, A., Campanella, C., Logozzi, M., Fais, S., Bucchieri, F., Cappello, F., & Caruso Bavisotto, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155432 · Cited by 58
“Ringsdorf properly described the concept of polymers and biopolymers-conjugated drugs in 1975 [44].”
BackgroundSequence-Defined Synthetic Polymers for New-Generation Functional Biomaterials
Deng, Z., Shi, Q., Tan, J., Hu, J., & Liu, S. (2021) · ACS Materials Letters · doi:10.1021/acsmaterialslett.1c00358 · Cited by 72
Recent progress in drug delivery of pluronic P123: pharmaceutical perspectives
Zhao, L., & Zhang, W. (2017) · Journal of drug targeting · doi:10.1080/1061186x.2017.1289538 · Cited by 67
“The rationale of application of polymers as carriers for conjugated therapeutic agents was introduced by Ringsdorf in 1975 [66].”
BackgroundMacromolecular systems for chemotherapy and magnetic resonance imaging
Matthews, S. E., Pouton, C. W., & Threadgill, M. D. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00098-r · Cited by 70
Xu, Z., Wang, D., Xu, S. H., Liu, X., Zhang, X., & Zhang, H. (2013) · Chemistry - An Asian Journal · doi:10.1002/asia.201301030 · Cited by 66
Biodegradable polymers I. Synthesis of hydrolysis-sensitive poly[(organo)phosphazenes]
Crommen, J. H. L., Schacht, E. H., & Mense, E. H. G. (1992) · Biomaterials · doi:10.1016/0142-9612(92)90102-t · Cited by 66
Poly(amidoamine) Conjugates Containing Doxorubicin Bound via an Acid‐Sensitive Linker
Lavignac, N., Nicholls, J. L., Ferruti, P., & Duncan, R. (2009) · Macromolecular Bioscience · doi:10.1002/mabi.200800163 · Cited by 64
Bacterial ghosts as a novel advanced targeting system for drug and DNA delivery
Paukner, S., Stiedl, T., Kudela, P., Bízik, J., Laham, F. A., & Lubitz, W. (2005) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.11 · Cited by 65
“The first soluble carrier system introduced by Ringsdorf was a polymeric carrier system of polyorthoesters [2].”
BackgroundNew Perspectives of HPMA‐based Copolymers Derived by Post‐Polymerization Modification
Nuhn, L., Barz, M., & Zentel, R. (2014) · Macromolecular Bioscience · doi:10.1002/mabi.201400028 · Cited by 65
A review on engineering polymer drug conjugates to improve combination chemotherapy
Vogus, D. R., Krishnan, V., & Mitragotri, S. (2017) · Current Opinion in Colloid & Interface Science · doi:10.1016/j.cocis.2017.08.002 · Cited by 68
Strategies To Design and Synthesize Polymer‐Based Stimuli‐Responsive Drug‐Delivery Nanosystems
Qin, X., & Li, Y. (2019) · ChemBioChem · doi:10.1002/cbic.201900550 · Cited by 65
Šírová, M., Strohalm, J., Šubr, V., Plocová, D., Rossmann, P., Mrkvan, T., Ulbrich, K., & Říhová, B. (2006) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-006-0168-0 · Cited by 65
“The concept of macromolecular carriers of low-molecular-weight (anti-cancer) drugs has evolved continuously over the last century, being started in 1906 with the Ehrlich’s ‘‘magic bullet’’ phrase [1] and accomplished with the concept of the use of polymers as targeted drug carriers by Ringsdorf in 1975 [2].”
BackgroundSoluble synthetic polymers in biological systems
Drobnik, J., & Rypáček, F. (1984) · Advances in polymer science · doi:10.1007/3-540-12796-8_9 · Cited by 72
American Cancer Society ( ACS )
Higgins, C. S., Martin, T. J., & Roginski, A. M. (2014) · Wiley eBooks · doi:10.1002/9781118660584.ese0105 · Cited by 65
Gianasi, E., Buckley, R. G., Latigo, J., Wasil, M., & Duncan, R. (2002) · Journal of Drug Targeting · doi:10.1080/1061186021000072456 · Cited by 64
“mid-1970s (Ringsdorf, 1975) to promote tumor targeting.”
BackgroundPolymer-drug conjugates: revolutionizing nanotheranostic agents for diagnosis and therapy
Parashar, A. K., Saraogi, G. K., Jain, P. K., Kurmi, B. D., Shrivastava, V., & Arora, V. (2024) · Discover Oncology · doi:10.1007/s12672-024-01509-9 · Cited by 63
“Since the conceptual framework proposed by Helmut Ringsdorf in 1975, PDCs have undergone substantial evolution, improving drug solubility, stability, and biodistribution while reducing the undesirable systemic side effects often associated with traditional therapies [4].”
BackgroundDesign of smart HPMA copolymer-based nanomedicines
Yang, J., & Kopec̆ek, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.003 · Cited by 65
“In 1975 Ringsdorf first clearly presented the concept of the use of polymers as targetable drug carriers [14].”
Polyphenols delivery by polymeric materials: challenges in cancer treatment
Vittorio, O., Curcio, M., Cojoc, M., Goya, G. F., Hampel, S., Iemma, F., Dubrovska, A., & Cirillo, G. (2017) · Drug Delivery · doi:10.1080/10717544.2016.1236846 · Cited by 66
“According to the Ringsdorf model (Ringsdorf, 1975), a water-soluble polymeric–drug conjugate consist of three different units (Sobczak et al., 2013): the drug-linking portion, a moiety responsible for the physicochemical properties; a third unit incorporating an active targeting element (e.g.…”
MethodBIODEGRADATION OF POLYMERS FOR BIOMEDICAL USE
Kopec̆ek, J. (1982) · Elsevier eBooks · doi:10.1016/b978-0-08-026226-0.50026-9 · Cited by 63
Nanomedicine from amphiphilized prodrugs: Concept and clinical translation
Xiang, J., Liu, X., Yuan, G., Zhang, R., Zhou, Q., Xie, T., & Shen, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114027 · Cited by 65
FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy
Yang, J., Zhang, R., Radford, D. C., & Kopeček, J. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.09.045 · Cited by 62
Abbasi, Y. F., Bera, H., Cun, D., & Yang, M. (2023) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2023.120797 · Cited by 65
Synthesis and study of controlled release of ibuprofen from the new acrylic type polymers
Babazadeh, M. (2006) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.02.032 · Cited by 61
Piotrowska, U., & Sobczak, M. (2014) · Molecules · doi:10.3390/molecules20010001 · Cited by 61
“In 1975 Helmut Ringsdorf proposed a model for the rational design of polymeric prodrug (Figure 1) [12,13].”
BackgroundMedical Use of Nanoparticles: Drug Delivery and Diagnosis Diseases
Nasimi, P., & Haidari, M. (2013) · International Journal of Green Nanotechnology · doi:10.1177/1943089213506978 · Cited by 61
An Integrated Approach for the Rational Design of Nanovectors for Biomedical Imaging and Therapy
Godin, B., Driessen, W. H. P., Proneth, B., Lee, S., Srinivasan, S., Rumbaut, R. E., Arap, W., Pasqualini, R., Mauro Ferrari, B., & Decuzzi, P. (2010) · Advances in genetics · doi:10.1016/s0065-2660(10)69009-8 · Cited by 60
“…nanovectors, metal nanoparticles for use in diagnostics, albumin paclitaxel nanoparticles approved for use in metastatic breast cancer, and drug– polymer constructs are also included (Zhang et al., 2007; Peer et al., 2007; Gradishar et al., 2005; Ringsdorf, 1975; Vasey et al., 1999; Allen, 2002).”
New strategies for polymer development in pharmaceutical science — a short review
Godwin, A., Bolina, K., Clochard, M.-C., Dinand, E., Rankin, S., Simic, S., & Brocchini, S. (2001) · Journal of Pharmacy and Pharmacology · doi:10.1211/0022357011776612 · Cited by 74
“…(Sprincl et al 1971, 1976), as prophylactics against radiation exposure (Ringsdorf et al 1971), and as pharmacologically active agents (Regelson 1968; Iliev et al 1974; Regelson et al 1974), Ringsdorf (1975) proposed that drugs and targeting moieties could be conjugated to water soluble polymers.”
BackgroundInfluentialPolymers for targeted and/or sustained drug delivery
Jagur‐Grodzinski, J. (2008) · Polymers for Advanced Technologies · doi:10.1002/pat.1304 · Cited by 68
Polymeric Nanocarriers for the Delivery of Antimalarials
Mhlwatika, Z., & Aderibigbe, B. A. (2018) · Molecules · doi:10.3390/molecules23102527 · Cited by 63
“The concept of polymer-drug conjugates was first reported by Helmut Ringsdorf in 1975 [69].”
BackgroundTheranostic systems assembled in situ on demand by host-guest chemistry
Jung, H., Park, K. M., Yang, J., Oh, E. J., Lee, D., Park, K., Ryu, S. H., Hahn, S. K., & Kim, K. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.06.060 · Cited by 60
“Since Ringsdorf proposed pharmacologically active polymers bearing multiple functional groups such as imaging probes, targeting moieties, cleavable spacers, chemical and biopharmaceutical drugs [1], huge progress has been made in the development of theranostic systems for a diagnostic therapy [2e8].”
BackgroundKinetics of water absorbency in AA/AMPS copolymers: applications of a diffusion–relaxation model
Rosa, F. C., Bordado, J. C., & Casquilho, M. (2002) · Polymer · doi:10.1016/s0032-3861(01)00596-1 · Cited by 60
PEG-Derivatized Dual-Functional Nanomicelles for Improved Cancer Therapy
Li, Y., Zhang, T., Liu, Q., & He, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00808 · Cited by 62
“Since Ringsdorf proposed the concept of “polymeric prodrug” in 1975, the utility of polymer-drug conjugates in clinical therapy has been well demonstrated (Hoste et al., 2004; Ringsdorf, 2010).”
BackgroundLei, M., Chen, G., Zhang, M., Lei, J., Li, T., Li, D., & Zheng, H. S. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.111750 · Cited by 59
Microstructural analysis of poly(glycidyl methacrylate) by 1H and 13C NMR spectroscopy
Espinosa, M. H., del Toro, P. J. O., & SILVA, D. Z. (2001) · Polymer · doi:10.1016/s0032-3861(00)00253-6 · Cited by 59
Dendrimers in Cancer Treatment and Diagnosis
Sampathkumar, S., & Yarema, K. J. (2003) · Wiley eBooks · doi:10.1002/9783527610419.ntls0071 · Cited by 59
Wang, H., He, J., Cao, D., Zhang, M., Li, F., Tam, K. C., & Ni, P. (2015) · Polymer Chemistry · doi:10.1039/c5py00569h · Cited by 59
Li, Y., Lu, H., Liang, S., & Xu, S. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b03960 · Cited by 59
Metadata
- Authors
- Ringsdorf, H.
- Affiliations
- Johannes Gutenberg University Mainz (DE)
- Corresponding author
- Ringsdorf, Helmut
- Venue
- Journal of Polymer Science: Polymer Symposia
- Publisher
- Wiley
- Published
- 1975-01
- Volume
- 51
- Issue
- 1
- Pages
- 135-153
- ISSN
- 0360-8905 (ISSN-L)
- 1936-0959
- OpenAlex
- W2098279377
- Cited by
- 1,094
- References
- 63
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 34 · 2023: 35 · 2022: 30 · 2021: 35 · 2020: 50 · 2019: 36 · 2018: 29 · 2017: 46 · 2016: 45 · 2015: 47 · 2014: 55 · 2013: 43 · 2012: 48
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Polymer Science Polymer Symposia (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Advanced Polymer Synthesis and Characterization
- Physical Sciences › Materials Science › Biomaterials › Hydrogels: synthesis, properties, applications
- Keywords
- macromolecular drugs, comonomer incorporation, polymer-analogous reactions, solubility, toxicity, body distribution, polymer synthesis, biological activity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.